approval
saveGLYXAMBI (EMPAGLIFLOZIN) — FDA approval
community read0 votes
Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalOct 24, 2025 · 346d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalOct 30, 2023 · 1071d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022 · 1453d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalMar 21, 2022 · 1659d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021 · 1942d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalMar 30, 2020 · 2380d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalJan 24, 2020 · 2446d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalJul 3, 2019 · 2651d ago
same company · ±60 days · 6
- approvalSYNJARDY: JARDIANCE (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021
- approvalSYNJARDY: JARDIANCE (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021
- approval(empagliflozin + linagliptin): GLYXAMBI (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021
- approval(empagliflozin + metformin hydrochloride ER): SYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021
- approval(empagliflozin + metformin hydrochloride ER): SYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021
- approval(empagliflozin + linagliptin + metformin hydrochloride) ER: TRIJARDY XR (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021
comments(0)
5-min edit window · permanent after that